<DOC>
	<DOCNO>NCT01369225</DOCNO>
	<brief_summary>This study evaluate safety tolerability multiple dose AAB-003 ( PF-05236812 ) patient mild moderate Alzheimer 's Disease . Patients complete study B2601001 may participate trial receive AAB-003 ( PF-05236812 ) . Each patient 's participation last approximately 52 week .</brief_summary>
	<brief_title>Open Label Extension Study Evaluating Safety Tolerability AAB-003 ( PF-05236812 ) Subject With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Successful completion study B2601001 MMSE 12 great Study B2601001 Week 32 MRI clinically important exclusionary finding . Experienced SAE , vasogenic edema and/or intracranial hemorrhage study B2601001</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Safety Study</keyword>
	<keyword>Open Label</keyword>
</DOC>